CVS Coverage Plan For New Drugs Tied To Outside Pricing Review Draws Criticism From Advocacy Groups
Also, market news is on Johnson & Johnson's new information officer from Bayer and why lifesaving drugs might be missing from flights.
Reuters:
CVS Drug Coverage Plan Based On Outside Pricing Review Is Off To A Slow Start
A CVS Health Corp health plan that uses an outside drug pricing group to help it decide whether to cover certain new medicines has gained little traction with customers, according to its top medical executive, and has drawn fierce criticism from patient advocacy groups. The company has held back on marketing the pharmacy benefit plan while it talks to these groups, CVS said. (Humer, 10/3)
The Wall Street Journal:
Bayer Executive Joins Johnson & Johnson As CIO
Jim Swanson, formerly a technology executive at Bayer AG ’s crop-science division, has joined Johnson & Johnson as chief information officer. He succeeds Stuart McGuigan, who was CIO at J&J for seven years and now runs information technology at the State Department. (Castellanos, 10/3)
The New York Times:
Why Lifesaving Drugs May Be Missing On Your Next Flight
Epinephrine, or adrenaline, is one of a handful of lifesaving drugs that are supposed to be “no-go” items for commercial passenger planes. According to federal regulations, flights are not supposed to take off without these medicines. Citing chronic drug shortages, however, the Federal Aviation Administration has granted airlines exemptions that permit passenger planes to fly without a complete medical kit if the airlines say they cannot replenish the drugs. The exemptions apply to international as well as domestic flights. (Caryn Rabin, 10/3)
